Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93


Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia.

Gejl M, Egefjord L, Lerche S, Vang K, Bibby BM, Holst JJ, Mengel A, Møller N, Rungby J, Brock B, Gjedde A.

J Cereb Blood Flow Metab. 2012 Dec;32(12):2146-52. doi: 10.1038/jcbfm.2012.118. Epub 2012 Aug 29.


Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans.

Lerche S, Brock B, Rungby J, Bøtker HE, Møller N, Rodell A, Bibby BM, Holst JJ, Schmitz O, Gjedde A.

Diabetes. 2008 Feb;57(2):325-31. Epub 2007 Nov 8.


Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain.

Gejl M, Lerche S, Egefjord L, Brock B, Møller N, Vang K, Rodell AB, Bibby BM, Holst JJ, Rungby J, Gjedde A.

Front Neuroenergetics. 2013 Mar 27;5:2. doi: 10.3389/fnene.2013.00002. eCollection 2013.


Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.

Gejl M, Søndergaard HM, Stecher C, Bibby BM, Møller N, Bøtker HE, Hansen SB, Gjedde A, Rungby J, Brock B.

J Clin Endocrinol Metab. 2012 Jul;97(7):E1165-9. doi: 10.1210/jc.2011-3456. Epub 2012 Apr 27.


Aqueous fraction of Beta vulgaris ameliorates hyperglycemia in diabetic mice due to enhanced glucose stimulated insulin secretion, mediated by acetylcholine and GLP-1, and elevated glucose uptake via increased membrane bound GLUT4 transporters.

Ul Kabir A, Samad MB, Ahmed A, Jahan MR, Akhter F, Tasnim J, Hasan SM, Sayfe SS, Hannan JM.

PLoS One. 2015 Feb 3;10(2):e0116546. doi: 10.1371/journal.pone.0116546. eCollection 2015.


At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose.

Gejl M, Rungby J, Brock B, Gjedde A.

Basic Clin Pharmacol Toxicol. 2014 Aug;115(2):162-71. doi: 10.1111/bcpt.12240. Epub 2014 Apr 30. Review.


Cerebral glucose transporter: the possible therapeutic target for ischemic stroke.

Zhang S, Zuo W, Guo XF, He WB, Chen NH.

Neurochem Int. 2014 May;70:22-9. doi: 10.1016/j.neuint.2014.03.007. Epub 2014 Mar 19. Review.


Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity.

Solomon TP, Knudsen SH, Karstoft K, Winding K, Holst JJ, Pedersen BK.

J Clin Endocrinol Metab. 2012 Dec;97(12):4682-91. doi: 10.1210/jc.2012-2097. Epub 2012 Oct 5.


Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.

Chen Z, Zhong C.

Prog Neurobiol. 2013 Sep;108:21-43. doi: 10.1016/j.pneurobio.2013.06.004. Epub 2013 Jul 11. Review.


Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.

Hompesch M, Jones-Leone A, Carr MC, Matthews J, Zhi H, Young M, Morrow L, Reinhardt RR.

Diabetes Obes Metab. 2015 Jan;17(1):82-90. doi: 10.1111/dom.12398. Epub 2014 Oct 26.


Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans.

Vollmer K, Gardiwal H, Menge BA, Goetze O, Deacon CF, Schmidt WE, Holst JJ, Meier JJ.

J Clin Endocrinol Metab. 2009 Apr;94(4):1379-85. doi: 10.1210/jc.2008-2197. Epub 2009 Jan 27.


Blood-brain barrier transport and brain metabolism of glucose during acute hyperglycemia in humans.

Hasselbalch SG, Knudsen GM, Capaldo B, Postiglione A, Paulson OB.

J Clin Endocrinol Metab. 2001 May;86(5):1986-90.


Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus.

McCormick LM, Heck PM, Ring LS, Kydd AC, Clarke SJ, Hoole SP, Dutka DP.

Cardiovasc Diabetol. 2015 Aug 8;14:102. doi: 10.1186/s12933-015-0259-3.


The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study.

Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M.

Crit Care. 2009;13(3):R67. doi: 10.1186/cc7874. Epub 2009 May 13.


[The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].

Escalada FJ.

Med Clin (Barc). 2014 Sep;143 Suppl 2:2-7. doi: 10.1016/S0025-7753(14)70101-0. Epub 2014 Oct 15. Spanish.


Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia.

Gejl M, Lerche S, Mengel A, Møller N, Bibby BM, Smidt K, Brock B, Søndergaard H, Bøtker HE, Gjedde A, Holst JJ, Hansen SB, Rungby J.

PLoS One. 2014 Jan 6;9(1):e83758. doi: 10.1371/journal.pone.0083758. eCollection 2014.


Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.

Pieber TR, Deller S, Korsatko S, Jensen L, Christiansen E, Madsen J, Heller SR.

Diabetes Obes Metab. 2015 Aug;17(8):742-50. doi: 10.1111/dom.12473. Epub 2015 May 20.


Nicotine pre-exposure reduces stroke-induced glucose transporter-1 activity at the blood-brain barrier in mice.

Shah KK, Boreddy PR, Abbruscato TJ.

Fluids Barriers CNS. 2015 Apr 29;12:10. doi: 10.1186/s12987-015-0005-y.


Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.

Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, Benhamed F, Grémeaux T, Drucker DJ, Kahn CR, Girard J, Tanti JF, Delzenne NM, Postic C, Burcelin R.

J Clin Invest. 2005 Dec;115(12):3554-63.

Supplemental Content

Support Center